Stanislaw M. Mikulski

2.5k total citations
41 papers, 1.8k citations indexed

About

Stanislaw M. Mikulski is a scholar working on Molecular Biology, Immunology and Oncology. According to data from OpenAlex, Stanislaw M. Mikulski has authored 41 papers receiving a total of 1.8k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Molecular Biology, 16 papers in Immunology and 11 papers in Oncology. Recurrent topics in Stanislaw M. Mikulski's work include Cancer-related Molecular Pathways (6 papers), Immunotherapy and Immune Responses (5 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Stanislaw M. Mikulski is often cited by papers focused on Cancer-related Molecular Pathways (6 papers), Immunotherapy and Immune Responses (5 papers) and Monoclonal and Polyclonal Antibodies Research (4 papers). Stanislaw M. Mikulski collaborates with scholars based in United States, Switzerland and India. Stanislaw M. Mikulski's co-authors include Wojciech Ardelt, Kuslima Shogen, Richard J. Youle, S.M. Rybak, Zbigniew Darżynkiewicz, Yanhong Wu, Dianne L. Newton, Shailendra K. Saxena, Susanna M. Rybak and Franco M. Muggia and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Oncology.

In The Last Decade

Stanislaw M. Mikulski

40 papers receiving 1.8k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stanislaw M. Mikulski United States 21 1.2k 374 291 209 203 41 1.8k
Kuslima Shogen United States 23 1.2k 1.0× 295 0.8× 160 0.5× 200 1.0× 152 0.7× 47 1.7k
Susanna M. Rybak United States 27 1.1k 0.9× 559 1.5× 200 0.7× 189 0.9× 73 0.4× 54 1.8k
Jarrett Adams Canada 24 1.1k 0.8× 548 1.5× 391 1.3× 183 0.9× 69 0.3× 53 1.9k
Ronald Ellis United States 20 1.6k 1.3× 339 0.9× 582 2.0× 111 0.5× 114 0.6× 46 2.6k
U.A. Ramagopal United States 27 1.1k 0.9× 1.0k 2.7× 628 2.2× 62 0.3× 74 0.4× 53 2.6k
Stanley M. Tahara United States 30 2.5k 2.0× 196 0.5× 197 0.7× 63 0.3× 52 0.3× 63 3.3k
Michael W. Spellman United States 24 1.9k 1.5× 617 1.6× 80 0.3× 167 0.8× 64 0.3× 27 2.8k
Gábor Pál Hungary 25 736 0.6× 761 2.0× 193 0.7× 52 0.2× 86 0.4× 62 1.9k
Elizabeth Yelverton United States 8 1.3k 1.0× 938 2.5× 500 1.7× 250 1.2× 223 1.1× 8 2.9k
T. Jesse Kwoh United States 22 1.3k 1.1× 380 1.0× 294 1.0× 58 0.3× 70 0.3× 41 2.4k

Countries citing papers authored by Stanislaw M. Mikulski

Since Specialization
Citations

This map shows the geographic impact of Stanislaw M. Mikulski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stanislaw M. Mikulski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stanislaw M. Mikulski more than expected).

Fields of papers citing papers by Stanislaw M. Mikulski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stanislaw M. Mikulski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stanislaw M. Mikulski. The network helps show where Stanislaw M. Mikulski may publish in the future.

Co-authorship network of co-authors of Stanislaw M. Mikulski

This figure shows the co-authorship network connecting the top 25 collaborators of Stanislaw M. Mikulski. A scholar is included among the top collaborators of Stanislaw M. Mikulski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stanislaw M. Mikulski. Stanislaw M. Mikulski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Saxena, Shailendra K., Ravi Sirdeshmukh, Wojciech Ardelt, et al.. (2002). Entry into Cells and Selective Degradation of tRNAs by a Cytotoxic Member of the RNase A Family. Journal of Biological Chemistry. 277(17). 15142–15146. 89 indexed citations
2.
Mikulski, Stanislaw M.. (2002). Phase II Trial of a Single Weekly Intravenous Dose of Ranpirnase in Patients With Unresectable Malignant Mesothelioma. Journal of Clinical Oncology. 20(1). 274–281. 138 indexed citations
3.
Halicka, Dorota, Piotr Pożarowski, Wojciech Ardelt, et al.. (2002). Enhancement of activation-induced apoptosis of lymphocytes by the cytotoxic ribonuclease onconase (Ranpirnase). International Journal of Oncology. 21(6). 1245–50. 22 indexed citations
4.
Vogelzang, Nicholas J., et al.. (2001). A Phase II Trial of Weekly Intravenous Ranpirnase (Onconase®), a Novel Ribonuclease in Patients with Metastatic Kidney Cancer. Investigational New Drugs. 19(3). 255–260. 20 indexed citations
5.
Halicka, H. Dorota, T. Murakami, Abraham Mittelman, et al.. (2000). Induction of differentiation of leukaemic (HL‐60) or prostate cancer (LNCaP, JCA‐1) cells potentiates apoptosis triggered by onconase. Cell Proliferation. 33(6). 407–417. 19 indexed citations
6.
Lee, Intae, et al.. (2000). Tumoricidal effects of Onconase on various tumors. Journal of Surgical Oncology. 73(3). 164–171. 32 indexed citations
7.
Vasandani, Veena M., et al.. (1999). Interferon Enhances the Activity of the Anticancer Ribonuclease, Onconase. Journal of Interferon & Cytokine Research. 19(5). 447–454. 10 indexed citations
8.
Deptała, Andrzej, H. Dorota Halicka, Barbara Ardelt, et al.. (1998). Potentiation of tumor necrosis factor induced apoptosis by onconase.. International Journal of Oncology. 13(1). 11–6. 43 indexed citations
9.
Rybak, Susanna M., John W. Pearson, William E. Fogler, et al.. (1996). Enhancement of Vincristine Cytotoxicity in Drug-Resistant Cells by Simultaneous Treatment With Onconase, an Antitumor Ribonuclease. JNCI Journal of the National Cancer Institute. 88(11). 747–753. 63 indexed citations
10.
Newton, Dianne L., et al.. (1994). Characterization of the Mechanism of Cellular and Cell Free Protein Synthesis Inhibition by an Anti-tumor Ribonuclease. Biochemical and Biophysical Research Communications. 204(1). 156–162. 37 indexed citations
11.
Wu, Yanhong, Stanislaw M. Mikulski, Wojciech Ardelt, S.M. Rybak, & Richard J. Youle. (1993). A cytotoxic ribonuclease. Study of the mechanism of onconase cytotoxicity. Journal of Biological Chemistry. 268(14). 10686–10693. 198 indexed citations
12.
Mosimann, S.C., Kathy Johns, Wojciech Ardelt, et al.. (1992). Comparative molecular modeling and crystallization of P‐30 protein: A novel antitumor protein of Rana pipiens oocytes and early embryos. Proteins Structure Function and Bioinformatics. 14(3). 392–400. 14 indexed citations
13.
Mikulski, Stanislaw M., Alberto Viera, Wojciech Ardelt, H Menduke, & Kuslima Shogen. (1990). Tamoxifen and trifluoroperazine (Stelazine) potentiate cytostatic/cytotoxic effects of P‐30 protein, a novel protein possessing anti‐tumour activity. Cell Proliferation. 23(3). 237–246. 38 indexed citations
14.
Darżynkiewicz, Zbigniew, et al.. (1988). Cytostatic and Cytotoxic Effects of Pannon (P‐30 Protein), A Novel Anticancer Agent. Cell Proliferation. 21(3). 169–182. 119 indexed citations
15.
Mikulski, Stanislaw M., et al.. (1979). Aspergillus Vegetative Endocarditis and Complete Heart Block in a Patient with Acute Leukemia. CHEST Journal. 76(4). 473–476. 16 indexed citations
16.
Mikulski, Stanislaw M., Michael A. Chirigos, & Franco M. Muggia. (1978). Immune Modulation and Cancer Control. Advances in pharmacology. 15. 263–287. 5 indexed citations
17.
Mikulski, Stanislaw M. & Ronald Billing. (1977). Inhibition of lymphocyte-dependent antibody effector cell function by human anti-B-lymphocyte alloantiserum. Cellular Immunology. 28(1). 69–74. 6 indexed citations
18.
Mikulski, Stanislaw M. & Franco M. Muggia. (1977). The biologic activity of MER-BCG in experimental systems and preliminary clinical studies. Cancer Treatment Reviews. 4(2). 103–117. 13 indexed citations
19.
Mikulski, Stanislaw M., et al.. (1977). Inhibition of Effector Cell Function in Human Antibody-Dependent Cellular Cytotoxicity by Sera From Cancer Patients2. JNCI Journal of the National Cancer Institute. 58(5). 1485–1487. 14 indexed citations
20.
Mikulski, Stanislaw M.. (1977). Hypothetical considerations: Alloimmunization and cancer immunotherapy. Cancer Immunology Immunotherapy. 3(1). 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kuslima Shogen Breakdown of academic impact, for papers by Susanna M. Rybak Breakdown of academic impact, for papers by Jarrett Adams Breakdown of academic impact, for papers by Ronald Ellis Breakdown of academic impact, for papers by U.A. Ramagopal Breakdown of academic impact, for papers by Stanley M. Tahara Breakdown of academic impact, for papers by Michael W. Spellman Breakdown of academic impact, for papers by Gábor Pál Breakdown of academic impact, for papers by Elizabeth Yelverton Breakdown of academic impact, for papers by T. Jesse Kwoh
Rankless by CCL
2026